6 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 3 | Terminated 3 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | IGM Biosciences, Inc. | 97 | 2019-09-30 | 2024-07-24 |
| Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy Entospletinib, Rituximab, Cyclophosphamide - DLBCL | Phase 1 / Phase 2 | Terminated | The Lymphoma Academic Research Organisation | 25 | 2017-07-26 | 2020-09-02 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) Birabresib Dose 20 mg - AML Including AML de Novo and AML Secondary to MDS, DLBCL | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 9 | 2016-05-19 | 2022-09-13 |
| A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma SGN-CD19B - Non-Hodgkin Lymphoma, DLBCL | Phase 1 | Terminated | Seagen Inc. | 44 | 2016-02-01 | 2018-08-13 |
Lymphoma, Follicular (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma, B-Cell (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Disease Attributes (1) · Lymphoma, Non-Hodgkin (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Cyclophosphamide (1) · Doxorubicin (1) · LFB-R603 (1) · OTX015 (1) · Prednisone (1) · Rituximab (1) · SGN-CD19B (1) · Vincristine (1) · acalabrutinib (1) · ublituximab (1) · vistusertib (1)
Acerta Pharma BV (1) · IGM Biosciences, Inc. (1) · Merck Sharp & Dohme LLC (1) · Seagen Inc. (1) · TG Therapeutics, Inc. (1) · The Lymphoma Academic Research Organisation (1)
United States (4) · France (2) · Australia (1) · Belgium (1) · Czechia (1) · Italy (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Emmanuelle Tchernonog (1) · Gilles Salles (1) · Juan Pinelli, PA-C, MMSc (1) · Julien Depaus (1)
PMID 28903943, PMID 34269152, PMID 35538512
2015 (1)